ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.6314
0.00%
Brent Oil
76.495
0.00%
Bitcoin
97,943.10
-0.27%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE

  6. Mathios Refractory Sa (0F6J) Cotización

Mathios Refractory Sa

Mathios Refractory Sa (0F6J)

LSE
0.352
0.00
(0.00%)
Cerrado 05 Enero 10:30AM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
0.352
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
0.00
0.00 Rango del Día 0.00
0.352 Rango de 52 semanas 0.352
Capitalización de Mercado [m]
3.456M
Precio Anterior
0.352
Precio de Apertura
-
Hora
(O)
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
0.00
Acciones en circulación
9,819,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.98
Beneficio por acción (BPA)
-0.18
turnover
12.75M
Beneficio neto
-1.74M

Acerca de Mathios Refractory Sa

Sector
Concrete Work
Industria
Concrete Work
Sitio web
www.mathios.com
Sede
Athens, Attica, Grc
Fundado
-
Mathios Refractory Sa is listed in the Concrete Work sector of the London Stock Exchange with ticker 0F6J. The last closing price for Mathios Refractory was 0.35 €. Over the last year, Mathios Refractory shares have traded in a share price range of 0.352 € to 0.352 €.

Mathios Refractory currently has 9,819,000 shares in issue. The market capitalisation of Mathios Refractory is 3.46 € million. Mathios Refractory has a price to earnings ratio (PE ratio) of -1.98.

0F6J Últimas noticias

Más noticias
No news to show yet.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1000.3520.3520.35200DE
4000.3520.3520.35200DE
12000.3520.3520.35200DE
26000.3520.3520.35200DE
52000.3520.3520.35200DE
156000.3520.3520.35200DE
260000.3520.3520.35200DE

0F6J - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Mathios Refractory?
El precio actual de las acciones de Mathios Refractory es 0.352 €
¿Cuántas acciones de Mathios Refractory están en circulación?
Mathios Refractory tiene 9,819,000 acciones en circulación
¿Cuál es la capitalización de mercado de Mathios Refractory?
La capitalización de mercado de Mathios Refractory es EUR 3.46M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Mathios Refractory?
Mathios Refractory ha negociado en un rango de 0.352 € a 0.352 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Mathios Refractory?
El ratio precio/beneficio de Mathios Refractory es -1.98
¿Cuál es el ratio de efectivo a ventas de Mathios Refractory?
El ratio de efectivo a ventas de Mathios Refractory es 0.27
¿Cuál es la moneda de reporte de Mathios Refractory?
Mathios Refractory presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Mathios Refractory?
El último ingresos anual de Mathios Refractory es EUR 12.75M
¿Cuál es el último beneficio anual de Mathios Refractory?
El último beneficio anual de Mathios Refractory es EUR -1.74M
¿Cuál es la dirección registrada de Mathios Refractory?
La dirección registrada de Mathios Refractory es EPIDAVROU STR. 5, PIRAEUS, ATHENS, ATTICA, 18233
¿Cuál es la dirección del sitio web de Mathios Refractory?
La dirección del sitio web de Mathios Refractory es www.mathios.com
¿En qué sector industrial opera Mathios Refractory?
Mathios Refractory opera en el sector CONCRETE WORK

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discusión

Ver feed completo
Mr. Bill Mr. Bill 12 minutos hace
https://www.goodrx.com/well-being/sleep/how-to-sleep-with-sciatica
nowwhat2 nowwhat2 14 minutos hace
Could still just be climbing in sympathy w overall crypto mkt

Scathingly poor outlooks

https://www.youtube.com/watch?v=EOsjnOUAw14



https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

WONDF
DonVance DonVance 16 minutos hace
This will hit 1k this year I believe now.
MSTR
georgejjl georgejjl 16 minutos hace
How many of the 7 million Alzheimer’s patients in the USA are projected to be treated with the MAB infusions during 2025???

How many people with Alzheimer’s in the USA are projected to be treated with donepezil (Aricept) or memantine during 2025???

The treatment used t
AVXL
Mr. Bill Mr. Bill 17 minutos hace
Stretches https://www.healthline.com/health/back-pain/sciatic-stretches#sitting-spinal-stretch
Graniteguy Graniteguy 18 minutos hace
Doc and Investor posters here tend to be negatively biased which you whole heartedly champion, especially "Doc" who's medical opinion is at best questionable, and incredibly biased, to fit a narrative of constant failure for Anavex's Blarcamesine. The fact that you pile onto their "steaming pile of
AVXL
BDEZ BDEZ 20 minutos hace
The Russes hit the jackpot?
BDEZ BDEZ 21 minutos hace
40% of homicides in the US take place in districts with a Soros-funded prosecutor.

Biden gave him a Medal Of Freedom.

https://x.com/EndWokeness/status/1875725808071012529
BDEZ BDEZ 22 minutos hace
Not good, thanks for sharing.
sand sand 29 minutos hace
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 29 minutos hace
Moving hard soon 
EFSH
mining101 mining101 30 minutos hace
Superb
MEGL
benz280c benz280c 37 minutos hace
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 44 minutos hace
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 45 minutos hace
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 48 minutos hace
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 53 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 54 minutos hace
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 59 minutos hace
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 1 hora hace
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 1 hora hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 1 hora hace
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 1 hora hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD

Su Consulta Reciente

LSE
0F6J
Mathios Refractory
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados